Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

News

PSR Life Sciences Conference 28 November 2019: Anatara Life Sciences (ASX:ANR), Steve Lydeamore (CEO)

🕔12/13/2019 12:21:53 PM 423

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. During his presentation, Steve spoke to the Anatara story and the exciting year we have ahead with upcoming corporate milestones on both our human and animal health product opportunities.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Anatara Investor Presentation and Update

🕔11/28/2019 8:30:18 AM 1168

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the Pitt Street Research Life Sciences Conference, held in Sydney, NSW.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) R&D Tax Incentive Received

🕔11/22/2019 8:21:55 AM 1082

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $847,325 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.

Read Full Article

Anatara Lifsciences Ltd (ASX:ANR) CEO Steve Lydeamore To Present at the Pitt Street Research Life Sciences Conference

🕔11/18/2019 1:17:55 PM 1145

Anatara's CEO Steve Lydeamore has been invited to present at the Pitt Street Research Life Sciences Conference on the 28th November in Sydney. Any investors interested in attending these presentations are invited to reach out.

Read Full Article

FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Interview with CEO Steve Lydeamore

🕔11/15/2019 7:46:07 AM 1991

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address and AGM Presentation

🕔11/11/2019 11:29:07 AM 1071

As Anatara moves forward, the Board is confident in the knowledge that a substantial market opportunity for Detach(R) remains, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/23/2019 8:23:31 AM 1039

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Microcap Investment Conference, held in Melbourne, VIC.

Read Full Article

Anatara Lifesciences (ASX:ANR) "The Health Kick" podcast with Tim Boreham

🕔10/18/2019 9:52:35 AM 1216

Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Financial Report

🕔10/17/2019 10:27:27 AM 1142

Forecast expenditure for the December 2019 quarter is anticipated to increase as the Company advances the development of its Gastrointestinal Reprogramming (GaRP) dietary supplement. A refund from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme is anticipated to be received in December 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Reports Statistically Significant Animal Studies

🕔10/14/2019 10:13:52 AM 1162

Anatara Lifesciences Ltd (ASX:ANR) is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product.

Read Full Article
###

44,582 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 259) (Last 30 Days: 1856) (Since Published: 44582) 

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports